BioCentury
ARTICLE | Clinical News

Atrix completes Leuprogel Phase III for prostate cancer

November 21, 2000 8:00 AM UTC

ATRX completed enrollment of 110 patients in its Phase III study of 90-day subcutaneous Leuprogel leuprolide to treat advanced prostate cancer. Leuprogel is a gonadotropin-releasing hormone (GnRH) ago...